Clinical trial
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
NCT03198546 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 1, 2017
- Completion date
- August 1, 2036
- Enrollment
- 30 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
car, gpc3 gene inactivation, hepatocellular carcinoma, immunotherapy, squamous cell lung cancer, t cell